Scarica l'app Stockscreener
4.17
3.73%
0.15
Pre-mercato:
4.20
0.03
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.02
Aprire:
$4.06
Volume 24 ore:
862.31K
Relative Volume:
1.23
Capitalizzazione di mercato:
$173.22M
Reddito:
$114.20M
Utile/perdita netta:
$-3.08M
Rapporto P/E:
-10.73
EPS:
-0.3885
Flusso di cassa netto:
$-77.20M
1 W Prestazione:
+7.20%
1M Prestazione:
+25.23%
6M Prestazione:
+13.01%
1 anno Prestazione:
+34.95%
Intervallo 1D:
$4.05
$4.27
Intervallo di 1 settimana:
$3.64
$4.27
Portata 52W:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.17 | 173.22M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Agenus (AGEN) officer Garo Armen takes May 2026 salary in stock - Stock Titan
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update - Business Wire
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
AGEN SEC FilingsAgenus 10-K, 10-Q, 8-K Forms - Stock Titan
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill
[ARS] AGENUS INC SEC Filing - Stock Titan
Agenus (NASDAQ: AGEN) proxy outlines equity pool increase and option exchange - Stock Titan
AGENUS EV-to-OCF: -2.51 | Fairly Valued - GuruFocus
MSN Money - MSN
Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat
Director Susan B. Hirsch receives 105,000 Agenus (NASDAQ: AGEN) stock options - Stock Titan
Equity grants: Agenus (AGEN) awards 305,000 stock options to director-officer Buell - Stock Titan
[Form 4] AGENUS INC Insider Trading Activity - Stock Titan
Director Timothy Wright receives 105K AGEN (NASDAQ: AGEN) stock options grant - Stock Titan
Agenus (NASDAQ: AGEN) accounting chief awarded stock options in lieu of cash bonus - Stock Titan
Stock options granted to Agenus (AGEN) director and officer Armen Garo - Stock Titan
Agenus (AGEN) director Brian Corvese granted 210,000 stock options - Stock Titan
Agenus (AGEN) price target increased by 48.39% to 23.46 - MSN
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Agenus to Host First 2026 Stakeholder Webcast - The National Law Review
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs - 투데이안
Here's Why Agenus (AGEN) is a Strong Momentum Stock - Yahoo Finance
Agenus Q4 2025 earnings preview - MSN
AGEN (Agenus Inc.) Q4 2025 loss far narrower than expected, shares rise 3.23 percent in today’s session.Community Trade Ideas - Xã Thanh Hà
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com - Investing.com India
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 - BioSpace
Agenus designa a BAP Pharma como socio global exclusivo para BOT+BAL - The Joplin Globe
Agenus (NASDAQ: AGEN) director Armen receives 3,403 fully vested shares as salary - Stock Titan
Promising Phase I Results for BOT/BAL and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Oncodaily
Agenus presents four abstracts on cancer therapies at ASCO - Investing.com
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Agenus enters global partnership with BAP Pharma for investigational BOT+BAL access - Traders Union
Agenus (NASDAQ: AGEN) asks shareholders to approve 5M shares, highlights BOT+BAL data - Stock Titan
Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Agenus reports trial data for cancer drug combination therapy By Investing.com - Investing.com Australia
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer - Lelezard
Agenus (AGEN) Presents Promising Trial Results for Advanced Canc - GuruFocus
Agenus Reports Phase II Data Demonstrating Immune Reprogramming a - The National Law Review
Agenus reports trial data for cancer drug combination therapy - Investing.com
Agenus cancer drug combo kept 43% alive at 18 months in study - Stock Titan
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Eastern Progress
Can Agenus (AGEN) Run Higher on Rising Earnings Estimates? - Eastern Progress
April 2026 Overview Highlights BOT+BAL Progress in MSS Colorectal Cancer – Agenus - Oncodaily
Agenus unveils 2026 catalyst roadmap with focus on BOT plus BAL and BATTMAN expansion - Traders Union
Agenus : Corporate Overview - marketscreener.com
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):